Novavax, Inc. (NASDAQ:NVAX) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET
Company Participants
Erika Schultz - Senior Director, IR
John Jacob - President and CEO
Filip Dubovsky - CMO
John Trizzino - CCO and CBO
James Kelly - CFO
Conference Call Participants
Roger Song - Jefferies
Eric Joseph - JPMorgan
Brendan Smith - TD Cowen
Mayank Mamtani - B. Riley
Alec Stranahan - Bank of America
Vernon Bernardino - H.C. Wainwright
Operator
Ladies and gentlemen, thank you for standing by and welcome to the Novavax Second Quarter 2023 Financial Results and Operational Highlights Conference Call. At this time, all participant lines are in a listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Erika Schultz. You may begin.
Erika Schultz
Good morning and thank you all for joining us today to discuss our second quarter 2023 operational highlights and financial results. A press release announcing our results is currently available on our website at novavax.com, and an audio archive of this conference call will be available on our website later today.
Please turn to slide two. Before we begin with prepared remarks, I need to remind you that this presentation includes forward-looking statements, including information relating to the future of Novavax, its key strategic priorities, operating plans, objective, and prospects, full year 2023 financial guidance, its future financial or business performance, conditions or strategies, its partnership, anticipated timing and outcome of future regulatory filings and actions, and the ongoing development of its vaccine candidates, the global market opportunities for our vaccine candidates, our manufacturing capacity, and the future availability of our vaccine candidates, and key upcoming milestones.
Each forward-looking statement contained in this presentation is subject to risks and uncertainties that can cause actual results to differ materially from those projected in such statements.
Additional information regarding these factors appears under the heading Cautionary Note Regarding Forward-Looking Statements in the slide deck we issued this afternoon, and under the heading Risk Factors, and our most recent Form 10-K and subsequent Form 10-Q filed with the Securities and Exchange Commission and available www.sec.gov and on our website atnovavax.com as well as subsequent filings with the SEC.
The forward-looking statements in this presentation speak as of the original date of this presentation and we undertake no obligation to update or revise any of these statements.